ReviewClinical reviews in allergy & immunology2026
The SP-MrgprX2 Axis in Allergic Rhinitis: a Neuro-immune Paradigm Beyond IgE-mediated Inflammation.
Review in Clinical reviews in allergy & immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic rhinitis (AR) is traditionally defined as an IgE-mediated hypersensitivity disorder; however, this paradigm fails to explain the clinical heterogeneity observed in patients with persistent symptoms and poor therapeutic responsiveness. Emerging evidence indicates that neuro-immune interactions constitute a critical, yet underappreciated, layer of AR pathogenesis. Substance P (SP)-Mas-related G protein-coupled receptor X2 (MrgprX2) axis has recently been recognized as a central mediator of IgE-independent inflammation. Upon sensory neuron activation, SP is rapidly released and directly activates MrgprX2 on mast cells, initiating immediate inflammatory responses independent of FcεRI signaling. This pathway further drives epithelial barrier disruption and neutrophil-dominant inflammation, while sustained activation establishes neuro-immune positive feedback loops and central sensitization along the nose-brain axis, ultimately promoting chronicity and therapeutic refractoriness. Here, we integrate current evidence into a unified neuro-immune framework in which the SP-MrgprX2 axis orchestrates inflammation initiation, amplification, and maintenance beyond the classical IgE-dependent pathway. We further delineate its molecular recognition, signaling dynamics, and neuro-immune synapse organization, and discuss its crosstalk with broader inflammatory networks. On this basis, we propose mechanism-guided therapeutic strategies targeting distinct regulatory layers of this axis. Collectively, this review positions the SP-MrgprX2 axis as a key mechanistic bridge linking neural activation to chronic inflammation, advancing a neuro-immune paradigm that extends beyond IgE-mediated disease and providing a conceptual foundation for precision management of refractory AR.
Indexed as
Identifiers
42509489What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.